Remdesivir for the treatment of COVID-19
코로나19 치료제 렘데시비르
Article
[키워드] 95% CI
95% confidence interval
adverse event
adverse events
age
all-cause mortality
antiviral medicine
approach
authorisation
baseline
CENTRAL
certainty
certainty of evidence
chance
citation
clinical
Clinical improvement
Clinical outcome
clinical outcomes
clinical status
Cochrane COVID-19 Study Register
comparable
conducted
contribute
Controlled
controlled trials
coronavirus disease
coronavirus diseases
COVID-19
COVID-19 patient
COVID-19 patients
COVID-19 research
Data collection
decrease
defined
diagnosed
died
disease severity
Effect
Efficacy and safety
Emergency use
Ethnicity
evaluated
Evidence
excluded
FIVE
Future
Gender
high risk
High-flow oxygen
hospitalised
hospitalised patient
Hospitalised patients
identify
increase
index
individual
information
inhibit
initial
Invasive mechanical ventilation
lack
liberation
life
low-flow oxygen
maintain
Mask
mechanical ventilation
media
medRxiv
methodology
Missing data
missing value
missing values
Mortality
MOST
nasal prong
nasal prongs
need for oxygen
no difference
no effect
Non-invasive
non-invasive mechanical ventilation
non-invasive ventilation
observation
outcome
outcomes
oxygen
participant
Participants
Patient
Placebo
potential benefit
potential benefits
Quality of life
randomised
randomised controlled trial
Randomised controlled trials
RCT
RCTs
receive
recruit
registry
Remdesivir
reported
required
Respiratory Support
risk
risk difference
risk of bia
risk ratio
RoB 2
SARS-CoV-2
SARS-COV-2 infection
Science Citation Index
searched
Selection
Serious Adverse Event
Serious Adverse Events
severity
Source
standard care
subgroup
subgroups
supplemental oxygen
systematic review
Treatment
viral replication
Web of Science
WHO
WHO International Clinical Trials Registry Platform
worsening
[DOI] 10.1002/14651858.CD014962 PMC 바로가기 [Article Type] Article
[DOI] 10.1002/14651858.CD014962 PMC 바로가기 [Article Type] Article